AETNA BETTER HEALTH®  
Coverage Policy/Guideline  
Name: Taltz Page: 1 of 5 
Effective Date: 5/1/2024 Last Review Date: 12/2023, 
3/2024  
Applies to: ☐Illinois 
New Jersey 
Pennsylvania K ids ☐Florida
Maryland 
Virg inia    ☐Florida Kids 
☒ ☐☐
☐Michigan
☐ ☐Kentucky PRMD
Intent: 
The intent of this policy/guideline is to provide information to the prescribing practitioner 
outlining the coverage criteria for Taltz under the patient’s prescription drug benefit.  
Description:  
FDA-Approved Indications 
A. 
  
 Moderate to severe plaque psoriasis (PsO) in patients 6 years of age and older who are 
candidates for systemic therapy or phototherapy (Reference the Biological Response 
Modifiers (BRMs) in the Treatment of Plaque Psoriasis NJ Protocol) 
A.Adult patients with active psoriatic arthritis (PsA)  
B.Adult patients with active ankylosing spondylitis (AS) 
C.Adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with 
objective signs of inflammation 
All other indications are considered experimental/investigational and not medically 
necessary. 
Applicable Drug List: 
Taltz 
Policy/Guideline: 
Documentation: 
A. Ankylosing spondylitis (AS), non-radiographic axial spondyloarthritis (nr-axSpA), and psoriatic arthritis (PsA) 
1.Initial requests: Chart notes, medical record documentation, or claims historysupporting previous medications tried (if applicable), including response to therapy. 
If therapy is not advisable, documentation of clinical reason to avoid therapy. 
2.Continuation requests: Chart notes or medical record documentation supportingpositive clinical response. 
Prescriber Specialty: 
This medication must be prescribed by or in consultation with one of the following: 
A. 
 Psoriatic arthritis: rheumatologist or dermatologist 
B.Ankylosing spondylitis and non-radiographic axial spondyloarthritis: rheumatologist 
Criteria for Initial Approval: 
AETNA BET
TER HEALTH®  
Coverage Policy/Guideline  
Name:  Taltz  Page: 2 of 5 
Effective Date:  5/1/2024  Last Review Date:  12/2023, 
3/2024  
Applies 
to: ☐Illinois  ☐Florida    ☐Florida Kids  
☒New Jersey  ☐Maryland  ☐Michigan
☐Pennsylvania  Kids  ☐Virginia  ☐Kentucky PRMD
A. P soriatic arthritis (PsA)  
1.A
uthorization of 12 months may be granted for adult members who have previously
received a biologic or targeted synthetic drug (e.g., Rinvoq, Otezla) indicated for active psoriatic arthritis.  
2.A uthori
zation of 12 months may be granted for adult members for treatment of active
psoriatic arthritis when either of the following  criteria is met:
i.Mem
ber has mild to moderate disease and meets one of the following criteria:
a.M
ember has had an inadequate response to methotrexate, leflunomide, or
another conventional synthetic drug (e.g., sulfasalazine) administered at anadequate dose and duration.
b.M
ember has an intolerance or contraindication to methotrexate or
leflunomide (see Appendix), or another conventional synthetic drug (e.g.,
sulfasalazine).
c.Mem
ber has enthesitis or predominantly axial disease.
ii.Mem
ber has severe disease.
B. A nkylo
sing spondylitis (AS) and non -radiographic axial spondyloarthritis (nr -axSpA)  
1.A
uthorization of 12 months may be granted for adult members who have previously
received a biologic or targeted synthetic drug (e.g., Rinvoq, Xeljanz) indicated for 
active ankylosing spondylitis or active non-radiographic axial spondyloarthritis . 
2.A uthori
zation of 12 months may be granted for adult members for treatment of active
ankylosing spondylitis or active non -radiographic axial spondyloarthritis when any of
the following criteria is met:
i.M
ember has had an inadequate response to at least two non -steroidal anti -
inflammatory drugs (NSAIDs).
ii.M
ember has an intolerance or contraindication to two or more NSAIDs.
Contin
uation of Therapy:  
A. P soriati
c arthritis (PsA)  
A
uthorization of 12 months may be granted for all adult members (including new 
members) who are using the requested medication for psoriatic arthritis and who 
achieve or maintain a  positive clinical response as evidenced by low disease activity or 
improvement in signs and symptoms of the condition when there is improvement in any 
of the following from baseline:  
1.N
umber of swollen joints
AETNA BET
TER HEALTH®  
Coverage Policy/Guideline  
Name:  Taltz  Page: 3 of 5 
Effective Date:  5/1/2024  Last Review Date:  12/2023, 
3/2024  
Applies 
to: ☐Illinois  ☐Florida    ☐Florida Kids  
☒New Jersey  ☐Maryland  ☐Michigan
☐Pennsylvania  Kids  ☐Virginia  ☐Kentucky PRMD
2.Num ber of tender joints
3.Da
ctylitis
4.
Enthesitis
5.A
xial disease
6.S
kin and/or nail involvement
B. A nkylo
sing spondylitis (AS) and non -radiographic  axial spondyloarthritis (nr- axSpA)  
A
uthorization of 12 months may be granted for all adult members (including new 
members) who are using the requested medication for ankylosing spondylitis or non-
radiographic axial spondyloarthritis  and who achieve or maintain a positive clinical 
response as evidenced by low disease activity or improvement in signs and symptoms 
of the condition when there is improvement in any of the following from baseline:  
1.F
unctional status
2.To
tal spinal pain
3.Inf
lammation (e.g., morning stiffn ess)
Other Cri
teria:  
Member has had a documented negative tuberculosis (TB) test (which can include a 
tuberculosis skin test [PPD], an interferon -release assay [IGRA], or a chest x -ray)*  within 6 
months of initiating therapy for persons who are naïve to biologic drugs or targeted 
synthetic drugs associated with an increased risk of TB.  
* If the sc
reening testing for TB is positive, there must be further testing to confirm there is
no active disease. Do not administer the requested medication to members with active TB infection. If there is latent disease, TB treatment must be started before initiation of the requested medication.  
Member ca
nnot use the requested medication concomitantly w ith any other biologic drug 
or targeted synthetic drug. 
APPENDIX
 
Examples
 of Clinical Reasons to Avoid Pharmacologic Treatment with Methotrexate, 
Cyclosporine, Acitretin, or Leflunomide  
1.C
linical diagnosis of alcohol use disorder, alcoholic liver disease,  or other chronic liver
disease   
2.D
rug interaction
3.Ris
k of treatment -related toxicity
AETNA BETTER HEAL
TH®  
Coverage Policy/Guideline  
Name:  Taltz  Page: 4 of 5 
Effective Date:  5/1/2024  Last Review Date:  12/2023, 
3/2024  
Applies 
to: ☐Illinois  ☐Florida    ☐Florida Kids  
☒New Jersey  ☐Maryland  ☐Michigan
☐Pennsylvania  Kids  ☐Virginia  ☐Kentucky PRMD
4.Pregnancy or currently planning pregnancy
5.Breastfeeding
6.Significant comorbidity prohibits use of systemic agents (e.g., liver or kidney disease,blood dyscrasias, uncontrolled hypertension)
7.Hypersensitivity
8.History of intolerance or adverse event
Approval Duration  and Quantity Restrictions : 
Approval:   
Initial and Renewal Approval: 12 months  
Quantity Le
vel Limit:   
Taltz (ixekizumab) 80 mg/mL prefilled syringe/autoinjector  
•Standard Limit: 1 syringe/ autoinjector per 28 days
•Exception Limit: 8 syringes/ autoinjectors per 84 days
FDA -Recommended Dosing : 
Plaque psoriasis with or without coexistent psoriatic arthritis, adults:  
•160 mg at week 0, followed by 80 mg at weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4weeks 
B. Pl aque psoriasis, pediatric (6 years and older)  (Reference the Biological  Response 
Modifiers ( BRMs) in the Treatment of Plaque Psoriasis  NJ Protocol ): 
•Les
s than 25 kg: 40 mg at week 0, then 20 mg every 4 weeks
•25 kg to 50 kg: 80 mg at week 0, then 40 mg every 4 weeks
•Greater than 50 kg: 160 mg at week 0, then 80 mg every 4 weeks
Psoriatic arth
ritis:  
•160 mg at week 0, followed by 80 mg every 4 weeks
Ankylosing spondylitis:  
•160 mg at week 0, followed by 80 mg every 4 weeks
Non -radiographic axi
al spondyloarthritis:  
•80 mg every 4 weeks
*Coverage 
up to the exception limits may be provided with prior authorization
AETNA BETTER HEAL
TH®  
Coverage Policy/Guideline  
Name:  Taltz  Page: 5 of 5 
Effective Date:  5/1/2024  Last Review Date:  12/2023, 
3/2024  
Applies 
to: ☐Illinois  ☐Florida    ☐Florida Kids  
☒New Jersey  ☐Maryland  ☐Michigan
☐Pennsylvania  Kids  ☐Virginia  ☐Kentucky PRMD
References:  
1. Taltz [package insert]. Indianapolis, IN: Eli Lilly and Company; September 2022.
2. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic
arthritis. Section 6: Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case -based
presentations and evidence -based conclusions. J Am Acad Dermatol. 2011;65(1):137 -174.
3. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriaticarthritis. Section 4: Guidelines of care for the management and treatment of psoriasis with traditional
systemic agents. J Am Acad Dermatol. 2009;61:451- 485.
4. Griffiths CE, Reich K, Lebwohl M, et al. Comparison of  ixekizumab  with etanercept or placebo in moderate-
to-severe psoriasis (UNCOVER -2 and UNCOVER -3): results from two phase 3 randomised trials.
Lancet.  2015;386(9993):541-51.
5. Gossec L , Baraliakos X, Kerschbaumer A, et al. European League Against Rheuma tism
(EULAR ) recommendations  for the  management  of psoriatic arthritis with pharmacological therapies: 2019
update. Ann Rheum Dis . 202 0;79(6):700- 712.
6. McInnes IB, Mease PJ, Kirkham B , et al. Secukinumab , a human ant i-interleukin -17A monoclonal antibody, in
patients with psoriatic arthritis (FUTURE 2): a randomised, double- blind, placebo -controlled, phase 3 trial.
Lancet . 2015;386(9999):1137- 46.
7. Menter A, Strober BE, Kaplan DH, et al. Joint AAD -NPF guidelines of care for the management and
treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029 -1072.
8. Testing for TB Inf ection. Centers for Disease Control and Prevention. Retrieved on January 11, 2023
from:  h
ttps://www.cdc.gov/tb/topic/basics/risk.htm .
9. Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the
management of ankylos ing spondylitis. Ann Rheum Dis  2011;70:896 –904.
10. Ward MM, Deodhar A, Gensler LS, et al. 2019 Update of the American College of Rheumatology/Spondylitis
Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the
treatment  of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol.
2019;71(10):1285 -1299.
11. Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation
Guideline for the Treatment of Psori atic Arthritis. Arthritis Rheum.  2018;71:5 -32.
12. Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis
(GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol.
2022;18 (8):465 -479.
13. Menter  A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology -National Psoriasis
Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies.  J Am
Acad Dermatol . 2020;82(6):1445 -1486.
14. Ramiro S, Nikiphorou E, S epriano A, et al. ASAS -EULAR recommendations for the management of axial
spondyloarthritis: 2022 update. Ann Rheum Dis.  2023;82:19 -34.
